Key Takeaway
CagriSema from Novo Nordisk represents the next evolution in weight management medication. This CagriSema Novo Nordisk resource covers the important information you need to make informed decisions.
Short answer
CagriSema combination claims need a high bar. A tested fixed-dose or protocolized combination is different from internet stack culture, where benefit, side effects, and attribution can become unclear fast.
CagriSema status snapshot ()
| Developer | Novo Nordisk |
| Mechanism | Fixed-dose cagrilintide plus semaglutide; amylin analogue plus GLP-1 receptor agonist biology. |
| Route | Once-weekly subcutaneous injection in phase 3 obesity studies. |
| U.S. status | Submitted to the FDA in December 2025; not FDA approved for chronic weight management as of April 27, 2026. |
| Global status | Regulatory review and additional phase 3/phase 3b studies. |
| Evidence to read first | REDEFINE 1 and REDEFINE 2 are the core obesity and obesity-with-type-2-diabetes studies. |
| Practical limit | The data are strong, but approval, label language, price, supply, and real-world adherence are still decisive. |
This page was upgraded to make the answer usable for traditional search, AI summaries, and human readers: status first, evidence second, and speculation clearly labeled.
CagriSema from Novo Nordisk represents the next evolution in weight management medication. This CagriSema Novo Nordisk resource covers the important information you need to make informed decisions. By combining semaglutide with a long-acting amylin analog called cagrilintide, this dual-mechanism drug has produced some of the highest weight loss numbers seen in clinical trials. If you have been following the GLP-1 space, CagriSema is one of the names you should know.
Key Takeaways: - Understand what is CagriSema and how does it work - Clinical Trial Results: Up to 25% Weight Loss - Expected Timeline and Availability - CagriSema vs. Other Dual-Mechanism Drugs
Here is what the science says and when you might be able to access it.
What Is CagriSema and How Does It Work?
CagriSema is a fixed-ratio combination of two medications in a single weekly injection. The first component is semaglutide, the well-known GLP-1 receptor agonist. The second is cagrilintide, a long-acting analog of amylin.
You're probably familiar with how semaglutide works. It activates GLP-1 receptors to reduce appetite, slow gastric emptying, and improve blood sugar control. For a full breakdown, see our .
Amylin is the newer piece of the puzzle. It's a hormone that your pancreas releases alongside insulin after you eat. Amylin slows stomach emptying, reduces glucagon secretion (which lowers blood sugar spikes), and activates brain pathways involved in satiety. It works through different receptors than GLP-1, meaning the two hormones provide complementary appetite suppression through separate mechanisms.
Think of it this way: GLP-1 turns down your hunger through one set of brain signals. Amylin turns down your hunger through a different set. When you combine both, you get stronger appetite suppression than either one alone.
"The key to successful GLP-1 therapy is setting realistic expectations and supporting patients through the titration phase. The side effects are manageable for most people, but they need to know what to expect.") Dr. Caroline Apovian, MD, Harvard Medical School
Pramlintide (Symlin) is an existing amylin analog used for diabetes. But it requires multiple daily injections and has limitations. Cagrilintide is a long-acting version designed for once-weekly dosing, making it practical to combine with weekly semaglutide.
Clinical Trial Results: Up to 25% Weight Loss
The Phase 3 trial results for CagriSema have been impressive. The REDEFINE program studied CagriSema across multiple patient populations.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
Free Download: GLP-1 Medication Comparison One-Pager See how CagriSema's weight loss data compares to semaglutide, tirzepatide, and other options. Get yours free (we'll email it to you instantly. [Email Input] [Download Button]
In the REDEFINE 1 trial, participants taking CagriSema lost approximately 22-25% of their body weight over 68 weeks. This puts CagriSema near the top of all weight management medications studied to date.
CagriSema also showed superiority over semaglutide alone. In head-to-head comparisons, the combination produced significantly more weight loss than the same dose of semaglutide by itself. This confirms that adding amylin provides a meaningful additional benefit.
The side effect profile was similar to other GLP-1 medications. Nausea, vomiting, and diarrhea were the most commonly reported adverse events. Rates were generally comparable to semaglutide alone, suggesting that adding cagrilintide doesn't dramatically increase gastrointestinal side effects.
Blood sugar improvements were also strong. CagriSema significantly reduced A1C in participants with type 2 diabetes, performing better than semaglutide alone.
For context on how these numbers compare to tirzepatide, read our .
Expected Timeline and Availability
Novo Nordisk has submitted regulatory filings for CagriSema based on the Phase 3 data. The FDA and European regulatory agencies are reviewing the applications.
Based on typical regulatory timelines, CagriSema could receive approval in late 2026 or early 2027. But approval doesn't guarantee immediate broad availability. Manufacturing scale-up, insurance negotiations, and distribution logistics all take time.
Pricing hasn't been officially announced. Given that CagriSema combines two active ingredients and is a premium product from Novo Nordisk, it will likely be priced at a premium compared to semaglutide alone.
If you're looking for effective treatment available today, FormBlends offers personalized compounded GLP-1 medications prescribed by licensed providers and prepared by US-based 503A pharmacies. You don't need to wait for CagriSema to start working toward your health goals.
CagriSema vs. Other Dual-Mechanism Drugs
CagriSema isn't the only dual-mechanism drug in development. Knowing how it compares helps you see the market.
CagriSema (GLP-1 + amylin) uses two appetite-suppressing hormones through different brain pathways. Weight loss in trials: approximately 22-25%.
Tirzepatide (GLP-1 + GIP) targets GLP-1 and GIP receptors to improve metabolic function and reduce appetite. Weight loss in trials: approximately 22%. It's already FDA-approved and available.
Survodutide (GLP-1 + glucagon) adds glucagon receptor activation to increase energy expenditure and promote liver fat breakdown. Phase 2 weight loss: approximately 19%. Still in Phase 3 trials.
Retatrutide (GLP-1 + GIP + glucagon) is the only triple agonist in development. Phase 2 weight loss: approximately 24%. Still in Phase 3 trials.
Each approach has unique advantages. CagriSema's amylin component specifically targets satiety pathways. Glucagon-containing drugs like survodutide may be better for liver health. Your provider can help you evaluate which mechanism best fits your health profile.
For a full comparison, visit our .
Frequently Asked Questions
What is cagrilintide?
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a hormone released by the pancreas that suppresses appetite, slows gastric emptying, and reduces blood sugar spikes. Cagrilintide is designed for once-weekly injection, making it practical to combine with semaglutide.
How much weight can you lose on CagriSema?
Phase 3 trials showed weight loss of approximately 22-25% of body weight over 68 weeks. This is among the highest weight loss numbers reported for any medication in clinical trials. Individual results vary based on diet, exercise, and other factors.
When will CagriSema be available?
CagriSema is currently under regulatory review. If approved, it could be available in late 2026 or early 2027. Manufacturing and insurance coverage timelines will affect broad availability.
Is CagriSema better than semaglutide alone?
In clinical trials, CagriSema produced significantly more weight loss than semaglutide alone. The addition of cagrilintide provides complementary appetite suppression through amylin pathways. But it's a new medication without the same long-term safety data as semaglutide, which has been studied extensively for years.
Can I get CagriSema through FormBlends?
CagriSema isn't yet available through any provider, as it hasn't received FDA approval. FormBlends currently offers effective compounded GLP-1 medications with licensed providers.
What's Your Next Move?
You have the information. Now let a licensed provider help you put it into action. FormBlends makes it simple, answer a few questions and get a personalized recommendation.
Medical References
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide with intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med. 2024. [PubMed | ClinicalTrials.gov | DOI]
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]
Sources &. References
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. Doi:10.1056/NEJMoa1411892
- Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. Doi:10.1056/NEJMoa1603827
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2[4] (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3[5] (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4[6] (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
This content is provided for informational and educational purposes only. It isn't a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed healthcare provider with any questions about a medical condition or treatment plan.
Last updated: 2026-03-24
What changed for CagriSema in 2026
The 2026 job is to separate the December 2025 U.S. filing and phase 3 results from an actual approved product. CagriSema has a credible late-stage evidence base, but routine U.S. prescribing still depends on FDA action and the final label.
For combination pages, that means tested combinations and unsupported stacks should never be treated as the same thing.
For the broader evidence map, read the CagriSema complete guide, then compare it with CagriSema clinical trial results: REDEFINE 1, REDEFINE 2, and what the numbers actually mean, CagriSema FDA approval timeline: filed in 2025, still waiting in 2026, and why the delay matters, CagriSema mechanism of action, without the fluff.
Claims we would not make yet
One of the easiest ways to over-optimize a pipeline page is to make it sound more certain than the evidence allows. For CagriSema, we would keep these boundaries explicit:
- Do not call CagriSema FDA approved until an FDA approval and label exist.
- Do not rank it above tirzepatide, semaglutide, or retatrutide as if there were a direct head-to-head tournament.
- Do not turn if-all-adhered trial estimates into guaranteed real-world results.
How to read the evidence without overclaiming
For CagriSema, the strongest answer is not the most dramatic answer. It is the answer that separates what has been shown, what is biologically plausible, and what still needs a label, trial readout, or real-world follow-up.
| Evidence layer | What it means for this page |
|---|---|
| Settled enough to state | Submitted to the FDA in December 2025; not FDA approved for chronic weight management as of April 27, 2026. Fixed-dose cagrilintide plus semaglutide; amylin analogue plus GLP-1 receptor agonist biology. |
| Useful but conditional | Novo reports 22.7% vs 2.3% weight loss in REDEFINE 1 and 15.7% vs 3.1% in REDEFINE 2 in if-all-adhered analyses at 68 weeks. This is useful context, but it still depends on population, duration, estimand, dose, and adherence. |
| Still unknown or changing | Long-term real-world persistence, payer behavior, comparative ranking, market access, and the exact patient groups most likely to benefit. |
Verification checklist for 2026
Before using this page to make a medical, investment, or content decision about CagriSema, verify the moving parts that can change fastest.
- Check whether the combination was tested as a protocol or is simply an unsupported stack idea.
- Confirm whether the page is written for the United States, China, Europe, or a global pipeline audience.
- Look for the current prescribing information when a product is approved; for investigational products, use the latest trial registry and sponsor update instead.
- Separate access from efficacy. A drug can look strong scientifically and still be unavailable, uncovered, or inappropriate for a specific patient.
Evidence ledger
The strongest version of this topic should cite primary or near-primary sources, not just repeat another SEO page. These are the sources this page should be checked against first:
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →